Effect of Obesity and Chronic Inflammation on TRAIL-Based Immunotherapy for Advanced Breast Cancer
Annual rept. 1 Apr 2013-31 Mar 2014
MINNESOTA UNIV MINNEAPOLIS
Pagination or Media Count:
Immune-based therapy for solid tumors is a promising area of research, providing the potential for cell-mediated immunotherapies to provide long-lived protection against various stage cancer. Unfortunately, even the most successful clinical trials using T cells or dendritic cells DC only show objective response rates in 50 of patients. This is due, in part, to a variety of tumor-derived immunosuppressive mechanisms that arise in cancer patients, rendering antitumor immune responses ineffective. In addition, epidemiological studies have demonstrated that obese individuals face an increased risk of developing cancers, including breast cancer. The reasons for this are likely complex and multifactorial, but a state of generalized immune suppression may contribute to these findings. Regardless of the body-mass index of the patient, successful long-term treatment of breast cancer must not only reduce the localized tumor burden, but must also target undetected or known metastases that may exist at the time the primary tumor is identified and treated.
- Medicine and Medical Research